- Vernakalant
Drugbox
IUPAC_name = (3"R")-1-{(1"R",2"R")-2- [2-(3,4-dimethoxyphenyl)
ethoxy] cyclohexyl}pyrrolidin-3-ol
CAS_number = 794466-70-9
CAS_supplemental = CAS|748810-28-8 (HCl)
ATC_prefix =
ATC_suffix =
PubChem = 9930049
DrugBank =
C=20|H=31|N=1|O=4
molecular_weight = 349.464 g/mol
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration = IntravenousVernakalant (INN; codenamed RSD1235, proposed tradename Kynapid) is an investigational drug under regulatory review for the acute conversion of
atrial fibrillation .It is being developed by Cardiome Pharma Corp.
On
December 11 ,2007 , the Cardiovascular and Renal Drugs Advisory Committee of the USFood and Drug Administration voted to recommend the approval of vernakalant. [cite web |url=http://www.drugs.com/nda/kynapid_071212.html |title=FDA Advisory Committee Recommends Approval of Kynapid for Acute Atrial Fibrillation
accessdate=2008-03-15 |format= |publisher=Drugs.com ]An oral formulation is currently undergoing Phase II clinical studies.
References
Wikimedia Foundation. 2010.
